2 results
Approved WMOWill not start
PRIMARY OBJECTIVE:To assess the safety and tolerability of MOR202 treatment in subjects with aMNKEY SECONDARY OBJECTIVE:To assess the effect of MOR202 on serum anti-PLA2R antibodies in subjects with aMNSECONDARY OBJECTIVES:1. To assess…
Approved WMOCompleted
Primary Objective:1. To evaluate the efficacy of sonelokimab at 2 different dose levels (120 mg, 240 mg) compared with placebo in the treatment of participants withactive moderate to severe hidradenitis suppurativa.Secondary Objectives:1. To…